Multi Cancer Early Detection Testing Market to Reach US$ 7.52 Billion by 2033 as Galleri, CancerSEEK, and Next-Gen Liquid Biopsies Lead Global Adoption

Global adoption is accelerating, led by GRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions. Investments from Roche's Foundation Medicine and biotech innovators such as Burning Rock, Lucence Health, and Freenome are further shaping the competitive landscape. Global adoption is accelerating, led byGRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions.Investments from...

Global adoption is accelerating, led by GRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions. Investments from Roche's Foundation Medicine and biotech innovators such as Burning Rock, Lucence Health, and Freenome are further shaping the competitive landscape.

Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market 

Browse in-depth TOC on 'Multi Cancer Early Detection Testing Market'

70 – Tables
66 – Figures
195 – Pages

Market Segmentation Analysis

By Test Type

Galleri Test, pioneered by GRAIL, dominated the market with over 40% share (US$ 770 million in 2024). Its ability to detect over 50 types of cancers with high specificity has made it the benchmark in MCED adoption across the U.S. and Europe.

CancerSEEK, developed through partnerships involving Johns Hopkins, captured 25% of the market (US$ 480 million). The test is expanding rapidly in colorectal, ovarian, and lung cancer detection.

By Cancer Type

Breast cancer led the segment in 2024 (US$ 420 million), supported by early detection programs in the U.S. and Japan.
Colorectal cancer and lung cancer together contributed US$ 620 million, as liquid biopsy solutions gain traction over invasive colonoscopies and imaging scans.
Blood cancers and prostate cancers, valued at US$ 480 million combined, are benefiting from MCED's non-invasive detection advantages.

By End-User

Hospitals & Clinics accounted for US$ 950 million in 2024, reflecting their role as the primary hubs for early cancer diagnosis.
Diagnostic laboratories generated US$ 690 million, with large lab chains partnering with biotech firms to expand access.
Academic & research institutes, valued at US$ 280 million, remain critical for clinical validation, biomarker discovery, and regulatory pathway advancement.

Regional Insights: USA & Japan

United States

The U.S. leads the MCED market with revenues exceeding US$ 920 million in 2024. Growth is fueled by:

Japan

Japan's MCED market, valued at US$ 190 million in 2024, is gaining momentum due to:

Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market 

Industry Trends & 2025 Developments

Competitive Landscape

GRAIL

GRAIL leads the MCED space with its Galleri Test, currently the most widely validated early detection test. Backed by Illumina and industry partnerships, GRAIL is expanding across North America, Europe, and Asia.

Guardant Health

Guardant has established itself as a liquid biopsy leader, leveraging genomic sequencing to detect early-stage cancers. In 2025, the company enhanced its MCED portfolio with AI-powered detection of gastrointestinal cancers.

Exact Sciences

Known for its Cologuard® test, Exact Sciences is expanding into MCED through partnerships with research institutes. Its multi-analyte testing platforms are positioned to capture share in colorectal and pancreatic cancers.

Burning Rock Biotech & Lucence Health

These companies are driving innovation in Asia, focusing on cost-effective, scalable MCED solutions. Their tests are gaining regulatory traction in Japan and China.

Roche's Foundation Medicine

Foundation Medicine brings strong diagnostic credibility, with 2025 developments focused on integrating MCED into comprehensive genomic profiling solutions.

Strategic Outlook

The MCED market is at a pivotal stage of evolution. Four themes define its future trajectory:

Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-testing-market 

Conclusion

The Multi Cancer Early Detection Testing Market, projected to grow from US$ 1.92 billion in 2024 to US$ 7.52 billion by 2033, is redefining global cancer care. With Galleri, CancerSEEK, Guardant Health, and Exact Sciences leading the innovation curve, MCED is positioned to transform survival outcomes by shifting cancer detection from late-stage diagnosis to early intervention.

Related Report:

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: [email protected] 

Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/multi-cancer-early-detection-testing-market-to-reach-us-7-52-billion-by-2033-as-galleri-cancerseek-and-next-gen-liquid-biopsies-lead-global-adoption-302577088.html